増加したベータ・トロンボグロブリン濃度および循環する血小板集積は,糖尿病の微血管病において見られる
Lancet (London, England)
|February 4, 1978
まとめ
糖尿病性微血管病は,ベータ・トロンボグロブリン (血小板タンパク質) と血小板活性化の増加と関連しています. 糖尿病患者の血糖コントロールの改善により,β-トロンボグロブリン濃度が著しく低下した.
科学分野:
- バイオケミストリー バイオケミストリー
- 血液学 ヘマトロジ
- エンドクリノロジー エンドクリノロジー
背景:
- 糖尿病性微血管病は,糖尿病の一般的な合併症である.
- 血小板活性化は,マイクロ血管疾患の病原性において潜在的な役割を果たします.
研究 の 目的:
- ベータ・トロンボグロブリン濃度,血小板結束,糖尿病微血管病の関係について調べる.
- これらのマーカーに対する血糖コントロールの影響を評価する.
主な方法:
- 血液サンプルは,健康な対照群と糖尿病患者 (微血管病と無病) から採取した.
- 測定には,β-トロンボグロブリン濃度と血小板総量比が含まれていました.
- 変化をモニターしたのは,血糖コントロールが改善された,新たに治療を受けた糖尿病患者でした.
主要な成果:
- マイクロアニオパシーを有する糖尿病患者は,ベータ-トロンボグロブリン濃度が著しく上昇したことを示した.
- また,これらの患者では,可逆的な血小板の集積も観察されました.
- 新たに治療を受けた9人の糖尿病患者の血糖コントロールの改善により,血ベータトロンボグロブリンが有意に減少しました.
結論:
- 糖尿病性微血管病は,血小板活性化の証拠と関連しています.
- 血小板特異のタンパク質であるβ-トロンボグロブリンが,この活性化のマーカーとして機能する可能性があります.
- 生化学的制御の程度は,糖尿病患者の血小板活性化に影響するようです.
関連する概念動画
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...